Rational Combinations of Targeted Agents in AML
Despite modest improvements in survival over the last several decades, the treatment of AML continues to present a formidable challenge. Most patients are elderly, and these individuals, as well as those with secondary, therapy-related, or relapsed/refractory AML, are particularly difficult to treat...
Main Authors: | Prithviraj Bose, Steven Grant |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/4/4/634 |
Similar Items
-
The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
by: Lanqin Wu, et al.
Published: (2019-08-01) -
Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy
by: Hoda Sobhy Ibrahim, et al.
Published: (2019-12-01) -
Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
by: Yu-Jun Dai, et al.
Published: (2021-01-01) -
Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia
by: Andrew Wei, et al.
Published: (2012-12-01) -
Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation
by: Alena Y. Streletskaia, et al.
Published: (2020-09-01)